Xaluprine (previously Mercaptopurine Nova Laboratories)

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

6-merkaptopurin monohidrat

Available from:

Nova Laboratories Ireland Limited

ATC code:

L01BB02

INN (International Name):

mercaptopurine

Therapeutic group:

Antineoplastična sredstva

Therapeutic area:

Leukemija, limfoid

Therapeutic indications:

Xaluprin je indiciran za liječenje akutne limfoblastične leukemije (ALL) u odraslih, adolescenata i djece.

Product summary:

Revision: 15

Authorization status:

odobren

Authorization date:

2012-03-09

Patient Information leaflet

                                23
B. UPUTA O LIJEKU
24
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
_ _
XALUPRINE 20 MG/ML ORALNA SUSPENZIJA
merkaptopurin
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se svom liječniku, ljekarniku
ili medicinskoj sestri.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika. To uključuje i svaku
moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte dio 4. _
_
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Xaluprine i za što se koristi
2.
Što morate znati prije nego počnete uzimati Xaluprine
3.
Kako uzimati Xaluprine
4.
Moguće nuspojave
5.
Kako čuvati Xaluprine
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE XALUPRINE I ZA ŠTO SE KORISTI
Xaluprine sadrži merkaptopurin. On pripada skupini lijekova koje
nazivamo citotoksični lijekovi
(zvani i kemoterapeutici).
Xaluprine se koristi za liječenje akutne limfoblastične leukemije
(koju također nazivamo i akutnom
limfocitnom leukemijom ili ALL). To je brzonapredujuća bolest koja
povećava broj novih bijelih
krvnih stanica. Te nove bijele krvne stanice su nezrele (nisu potpuno
oblikovane) te ne mogu rasti i
ispravno djelovati. Stoga se ne mogu boriti protiv infekcija i mogu
uzrokovati krvarenje.
Pitajte svog liječnika ako trebate više objašnjenja o ovoj bolesti.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE UZIMATI XALUPRINE
-
NEMOJTE UZIMATI XALUPRINE ako ste alergični na merkaptopurin ili neki
drugi sastojak ovog
lijeka (naveden u dijelu 6.).
-
NEMOJTE SE CIJEPITI cjepivom protiv žute groznice dok uzimate
Xaluprine jer to može biti
smrtonosno.
UPOZORENJA I MJERE OPREZA
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije
nego uzmete Xaluprine:
-
ako ste bili cijepljeni cjepivom protiv žute groznice
-
ako imate pr
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Xaluprine 20 mg/ml oralna suspenzija
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedan ml suspenzije sadrži 20 mg merkaptopurina (u obliku hidrata).
Pomoćna(e) tvar(i) s poznatim učinkom:
Jedan ml suspenzije sadrži 3 mg aspartama, 1 mg metilhidroksibenzoata
(u obliku natrijeve soli),
0,5 mg etilhidroksibenzoata (u obliku natrijeve soli) i saharozu (u
tragovima).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Oralna suspenzija.
Suspenzija je ružičaste do smeđe boje.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Xaluprine je indiciran za liječenje akutne limfoblastične leukemije
(ALL) u odraslih, adolescenata i
djece.
4.2
DOZIRANJE I NAČIN PRIMJENE
Liječenje Xaluprineom treba nadzirati liječnik ili drugi zdravstveni
radnici iskusni u liječenju
bolesnika s ALL-om.
Doziranje
Doza se pažljivo prilagođava uzimajući u obzir uočenu
hematotoksičnost i individualne potrebe
bolesnika u okviru aktivnog protokola liječenja. Ovisno o fazi
liječenja, početne ili ciljne doze
općenito se kreću između 25 i 75 mg/m
2
tjelesne površine po danu, ali bi trebale biti niže u bolesnika s
reduciranom ili odsutnom aktivnošću enzima tiopurin metiltransferaze
(TPMT) (vidjeti dio 4.4).
3
25 MG/M
2
50 MG/M
2
75 MG/M
2
TJELESNA
POVRŠINA
(m
2
)
Doza
(mg)
Volumen
(ml)
TJELESNA
POVRŠINA
(m
2
)
Doza
(mg)
Volumen
(ml)
TJELESNA
POVRŠIN
A (m
2
)
Doza
(mg)
Volumen
(ml)
0,20 - 0,29
6
0,3
0,20 - 0,23
10
0,5
0,20 - 0,23
16
0,8
0,30 - 0,36
8
0,4
0,24 - 0,26
12
0,6
0,24 - 0,26
20
1,0
0,37 - 0,43
10
0,5
0,27 - 0,29
14
0,7
0,27 - 0,34
24
1,2
0,44 - 0,51
12
0,6
0,30 - 0,33
16
0,8
0,35 - 0,39
28
1,4
0,52 - 0,60
14
0,7
0,34 - 0,37
18
0,9
0,40 - 0,43
32
1,6
0,61 - 0,68
16
0,8
0,40 - 0,44
20
1,0
0,44 - 0,49
36
1,8
0,69 - 0,75
18
0,9
0,45 - 0,50
24
1,2
0,50 - 0,55
40
2,0
0,76 - 0,84
20
1,0
0,51 - 0,58
28
1,4
0,56 - 0,60
44
2,2
0,85 - 0,99
24
1,2
0,59 - 0,66
32
1,6
0,61 - 0,65
48
2,4
1,0 - 1,16
28
1,4
0,67 - 0,74
36
1,8
0,66 - 0,70
52
2,6
1,17 - 1,33
32
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-05-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-05-2023
Public Assessment Report Public Assessment Report Bulgarian 27-09-2012
Patient Information leaflet Patient Information leaflet Spanish 25-05-2023
Public Assessment Report Public Assessment Report Spanish 27-09-2012
Patient Information leaflet Patient Information leaflet Czech 25-05-2023
Public Assessment Report Public Assessment Report Czech 27-09-2012
Patient Information leaflet Patient Information leaflet Danish 25-05-2023
Public Assessment Report Public Assessment Report Danish 27-09-2012
Patient Information leaflet Patient Information leaflet German 25-05-2023
Public Assessment Report Public Assessment Report German 27-09-2012
Patient Information leaflet Patient Information leaflet Estonian 25-05-2023
Public Assessment Report Public Assessment Report Estonian 27-09-2012
Patient Information leaflet Patient Information leaflet Greek 25-05-2023
Public Assessment Report Public Assessment Report Greek 27-09-2012
Patient Information leaflet Patient Information leaflet English 25-05-2023
Public Assessment Report Public Assessment Report English 27-09-2012
Patient Information leaflet Patient Information leaflet French 25-05-2023
Public Assessment Report Public Assessment Report French 27-09-2012
Patient Information leaflet Patient Information leaflet Italian 25-05-2023
Public Assessment Report Public Assessment Report Italian 27-09-2012
Patient Information leaflet Patient Information leaflet Latvian 25-05-2023
Public Assessment Report Public Assessment Report Latvian 27-09-2012
Patient Information leaflet Patient Information leaflet Lithuanian 25-05-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-05-2023
Public Assessment Report Public Assessment Report Lithuanian 27-09-2012
Patient Information leaflet Patient Information leaflet Hungarian 25-05-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 25-05-2023
Public Assessment Report Public Assessment Report Hungarian 27-09-2012
Patient Information leaflet Patient Information leaflet Maltese 25-05-2023
Public Assessment Report Public Assessment Report Maltese 27-09-2012
Patient Information leaflet Patient Information leaflet Dutch 25-05-2023
Public Assessment Report Public Assessment Report Dutch 27-09-2012
Patient Information leaflet Patient Information leaflet Polish 25-05-2023
Public Assessment Report Public Assessment Report Polish 27-09-2012
Patient Information leaflet Patient Information leaflet Portuguese 25-05-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 25-05-2023
Public Assessment Report Public Assessment Report Portuguese 27-09-2012
Patient Information leaflet Patient Information leaflet Romanian 25-05-2023
Public Assessment Report Public Assessment Report Romanian 27-09-2012
Patient Information leaflet Patient Information leaflet Slovak 25-05-2023
Public Assessment Report Public Assessment Report Slovak 27-09-2012
Patient Information leaflet Patient Information leaflet Slovenian 25-05-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 25-05-2023
Public Assessment Report Public Assessment Report Slovenian 27-09-2012
Patient Information leaflet Patient Information leaflet Finnish 25-05-2023
Public Assessment Report Public Assessment Report Finnish 27-09-2012
Patient Information leaflet Patient Information leaflet Swedish 25-05-2023
Public Assessment Report Public Assessment Report Swedish 27-09-2012
Patient Information leaflet Patient Information leaflet Norwegian 25-05-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 25-05-2023
Patient Information leaflet Patient Information leaflet Icelandic 25-05-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 25-05-2023